Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BOLAR/HERCON TRANSDERMAL NITROGLYERCIN PATCH SALES APPROACH $2 MIL. in the product's first two months on the market, Bolar President Robert Shulman told a David Saks' drug and health care seminar in New York on Oct. 28. "Bolar introduced the product in August 1986 and I believe we've sold approximately $2 mil. worth of it in September and October," Shulman reported. Acknowledging that much of the initial sell-in was from trade stocking, Shulman added that "reorders are starting to come in and it looks like this is going to stay with us and be a very good product." The transdermal nitroglyerin patch, designated NTS, was approved in April by FDA as an ANDA. Bolar began shipments to the trade in August after production scale-up and an early promotional effort during the summer. Hercon noted that Bolar is marketing NTS to distributors at approximately 50% of the price for Ciba-Geigy's Transderm-Nitro. Also speaking at the meeting put on by the Morgan, Olmstead, Kennedy & Gardner analyst, Hercon President Agis Kydonieus, PhD, said that in an 18-person bioequivalence study NTS "showed 99.9% bioequivalency to the [Marion's] Nitro-bid ointment." The Hercon exec noted that while Bolar is marketing the product itself, the generic firm is also selling the product to other generic drug marketers for private label marketing. Kydonieus said that Bolar "is selling the product to an additional seven or eight generic companies," including Rugby, Geneva, Major, Goldline, Bioline, Qualitest, and Lemmon. "In addition," Kydonieus said, "the product has been licensed in Germany, France, and Italy and we expect to start distributing the product in Europe early in 1987." Hercon's parent company, Health-Chem, announced in August that its subsidiary had signed an R&D agreement with Bolar worth approximately $4 mil. covering six additional transdermal generics ("The Pink Sheet" Aug. 25, T&G 1). Health-Chem noted at the time that three of the six products covered in the agreement have reached the human clinical testing stage. In all, Kydonieus said, Hercon has "about 40" drugs in different stages of development, including seven in clinical studies. Hercon has filed an ANDA for an undisclosed antihypertensive product, Kydonieus added.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts